Episode 180 - April 17, 2026

What It Covers

Biotech Hangout Episode 180 covers the XBI reaching post-pandemic highs, Kilera's $625M IPO, Revolution Medicines' pancreatic cancer data showing a 0.4 overall survival hazard ratio, Allogene's allogeneic CAR-T results, Spire's UC data, and the FDA's approval of sparsentan for FSGS despite a failed eGFR endpoint.

Key Questions Answered

• •XBI Construction Shift: The XBI's methodology has moved away from equal-weight across broad stocks toward weighting larger, more liquid companies. Investors should account for this when using XBI as a benchmark, as recent M&A activity among those larger constituents — not broad sector strength — is a primary driver of current index highs.
• •Revolution Medicines Valuation Signal: RevMed's pan-RAS combination therapy posted a 0.4 overall survival hazard ratio in second-line pancreatic cancer, pushing its market cap to roughly $30B as a development-stage company. Investors tracking pipeline-driven valuation should note the company raised $2B post-data, positioning for independent commercialization without a near-term acquisition.
• •FDA Endpoint Flexibility in Kidney Disease: Sparsentan received FSGS approval based on proteinuria reduction despite missing its eGFR endpoint in a two-year active-controlled phase 3 trial. Investors in kidney programs — particularly Vertex's enaxoquin phase 3 in APOL1 nephropathies — should monitor whether this precedent lowers the regulatory bar for eGFR requirements going forward.
• •Bootstrapped Biotech Exit Model: Crossbridge Bio raised only $10M via SAFE notes and seed funding, then exited to Lilly within 18 months at up to $300M, delivering a reported 17x return to early investors — without an open IND. Founders in preclinical oncology should consider lean capital strategies when pharma partnership interest is genuine and verifiable.
• •Allogeneic CAR-T Timing Risk: Allogene's semacel showed MRD negativity conversion in 12 frontline B-cell lymphoma patients, but the stock fell after a $175M offering priced below pre-data levels. Investors in cell therapy should factor in multi-year enrollment timelines and a 2027 interim analysis before sizing positions, as sentiment toward the modality remains broadly negative.